deCODE close to broke

Icelandic biotech deCODE Genetics may become another casualty of tough economic times. The company linkurl:announced today;http://tinyurl.com/rcf3pb (August 11) that it has only $3.8 million dollars left in its coffers -- enough to fund operations "into the latter half of the third quarter," which in Iceland runs through September. In a conference call this morning, the company said it was restructuring its business, dropping its medicinal chemistry and structural biology operations, and inste

Written byAlla Katsnelson
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Icelandic biotech deCODE Genetics may become another casualty of tough economic times. The company linkurl:announced today;http://tinyurl.com/rcf3pb (August 11) that it has only $3.8 million dollars left in its coffers -- enough to fund operations "into the latter half of the third quarter," which in Iceland runs through September. In a conference call this morning, the company said it was restructuring its business, dropping its medicinal chemistry and structural biology operations, and instead focusing on providing commercial and consumer genetics services. "We are making good progress in recasting deCODE as a leading DNA-based diagnostics company," Kari Stefansson, the company's CEO, said on the call. Going forward, said Stefansson, the three main elements of its business will be the company's consumer genome-based diagnostics business decodeME, as well as scientific services (providing genotyping, sequencing, and data management) and out-licensing for genetic markers. A $10 million deal struck in April, for example, granted genomics company Celera a license to use deCODE-discovered markers for cardiovascular and metabolic disease risk. More such deals, or an alternative infusion of funds, will be needed to keep the company in business, however. The company's stock hit bottom in October last year, though since mid-April it has been steadily increasing from approximately 20 cents a share to 65 cents a share. (Today's stock price as of noon EST is at 61 cents a share.) The company's fall would be "a substantial blow to the field of complex trait genetics," linkurl:the blog Genetic Future;http://scienceblogs.com/geneticfuture/2009/08/decode_genetics_on_the_brink_o.php pointed out, noting that deCODE has "generated an insanely large number of Nature Genetics publications."
**__Related stories:__***linkurl:One biotech gasps for breath;http://www.the-scientist.com/blog/display/55882/
[10th August 2009]*linkurl:DeCODE falls from NASDAQ grace;http://www.the-scientist.com/blog/display/55200/
[18th November 2008 ]*linkurl:Trouble for deCODE;http://www.the-scientist.com/blog/display/55089/
[14th October 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a woman with her hands across her stomach. She has a look of discomfort on her face. There is a blown up image of her stomach next to her and it has colorful butterflies and gut bacteria all swarming within the gut.
November 2025, Issue 1

Why Do We Feel Butterflies in the Stomach?

These fluttering sensations are the brain’s reaction to certain emotions, which can be amplified or soothed by the gut’s own “bugs".

View this Issue
Olga Anczukow and Ryan Englander discuss how transcriptome splicing affects immune system function in lung cancer.

Long-Read RNA Sequencing Reveals a Regulatory Role for Splicing in Immunotherapy Responses

Pacific Biosciences logo
Research Roundtable: The Evolving World of Spatial Biology

Research Roundtable: The Evolving World of Spatial Biology

Conceptual cartoon image of gene editing technology

Exploring the State of the Art in Gene Editing Techniques

Bio-Rad
Conceptual image of a doctor holding a brain puzzle, representing Alzheimer's disease diagnosis.

Simplifying Early Alzheimer’s Disease Diagnosis with Blood Testing

fujirebio logo

Products

Labvantage Logo

LabVantage Solutions Awarded $22.3 Million U.S Customs and Border Protection Contract to Deliver Next-Generation Forensic LIMS

The Scientist Placeholder Image

Evosep Unveils Open Innovation Initiative to Expand Standardization in Proteomics

OGT logo

OGT expands MRD detection capabilities with new SureSeq Myeloid MRD Plus NGS Panel